DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
for Relapsed Diffuse Large B-cell Lymphoma
Sites in Toledo +9 more locations
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
Sex: All·Age: 18+
Code: NCT04920617·Phase 2·Recruiting·Listed Jun 2021